摘要
作为一种重要的转录后修饰,组蛋白去乙酰化在染色质重塑和基因表达中起着重要作用。 组蛋白去乙酰化的异常修饰会导致各种疾病。 作为组蛋白去乙酰化酶 (HDAC) 的关键成员,HDAC6 在许多生理过程中充当关键调节剂。 HDAC6 的异常表达会导致癌症、神经变性和其他疾病。 在这里,我们回顾了 HDAC6 选择性抑制剂的生理学、蛋白质结构和开发方面的最新进展。
关键词: 转录后修饰,HDAC6,结构,癌症,选择性抑制剂,组蛋白去乙酰化。
Current Medicinal Chemistry
Title:Recent Development of Novel HDAC6 Isoform-selective Inhibitors
Volume: 28 Issue: 21
关键词: 转录后修饰,HDAC6,结构,癌症,选择性抑制剂,组蛋白去乙酰化。
摘要: As an important post-transcription modification, histone deacetylation plays significant roles in chromatin remodeling and gene expression. The aberrant modification of histone deacetylation leads to various diseases. As a critical member of histone deacetylase (HDAC), HDAC6 serves as a key modulator in many physiological processes. Abnormal expression of HDAC6 gives rise to cancer, neurodegeneration and other diseases. Here, we have reviewed recent advances in physiological, protein structure and development of HDAC6 selective inhibitors.
Export Options
About this article
Cite this article as:
Recent Development of Novel HDAC6 Isoform-selective Inhibitors, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666201111142653
DOI https://dx.doi.org/10.2174/0929867327666201111142653 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres
Current Pharmaceutical Design Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets The Chemical Methods of Disulfide Bond Formation and Their Applications to Drug Conjugates
Current Organic Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Hsp70 Protein Complexes as Drug Targets
Current Pharmaceutical Design Recent Progress in Therapeutic and Diagnostic Applications of Lanthanides
Mini-Reviews in Medicinal Chemistry Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Antibody Recognition of Fluorinated Haptens and Antigens
Current Topics in Medicinal Chemistry Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Molecular Targeting in Pancreatic Cancer
Reviews on Recent Clinical Trials Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Synthesis, Biological Evaluation and Molecular Docking Studies of Novel Trimethoxy-ring Derivatives as BRD4 Inhibitors
Letters in Drug Design & Discovery The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry